MedPath

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

Phase 2
Completed
Conditions
Ovarian Cancer Recurrent
Interventions
Registration Number
NCT01332656
Lead Sponsor
Sanofi
Brief Summary

Primary Objective:

- To demonstrate an improvement in Progression-Free Survival (PFS) for Ombrabulin versus placebo in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with paclitaxel and carboplatin.

Secondary Objectives:

* To compare the overall survival (OS) between the 2 treatment arms

* To compare the objective response rate (RR) between the 2 treatment arms

Detailed Description

Treatment will continue until disease progression or unacceptable toxicity or consent withdrawal. A minimum of 6 cycles of the combined therapies should be administered, unless progression occurs before or safety reasons cause the discontinuation of one or two drugs of the combination therapies. In case of no progression, it will be investigator's decision to continue or not the study treatment after 6 cycles according to his clinical practice.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
154
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm BPaclitaxelPlacebo, Paclitaxel and Carboplatin
Arm BPlaceboPlacebo, Paclitaxel and Carboplatin
Arm AOmbrabulin (AVE8062)Ombrabulin, Paclitaxel and Carboplatin
Arm APaclitaxelOmbrabulin, Paclitaxel and Carboplatin
Arm ACarboplatinOmbrabulin, Paclitaxel and Carboplatin
Arm BCarboplatinPlacebo, Paclitaxel and Carboplatin
Primary Outcome Measures
NameTimeMethod
Progression Free Survival (PFS)approximately 24 months
Secondary Outcome Measures
NameTimeMethod
Overall Survival (OS)approximately 24 months
Objective Response Rate (RR)approximately 24 months

Trial Locations

Locations (38)

Investigational Site Number 840002

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Investigational Site Number 203004

๐Ÿ‡จ๐Ÿ‡ฟ

Zlin, Czech Republic

Investigational Site Number 643003

๐Ÿ‡ท๐Ÿ‡บ

Moscow, Russian Federation

Investigational Site Number 724003

๐Ÿ‡ช๐Ÿ‡ธ

Madrid, Spain

Investigational Site Number 380001

๐Ÿ‡ฎ๐Ÿ‡น

Roma, Italy

Investigational Site Number 616005

๐Ÿ‡ต๐Ÿ‡ฑ

Warszawa, Poland

Investigational Site Number 056002

๐Ÿ‡ง๐Ÿ‡ช

Haine-Saint-Paul, Belgium

Investigational Site Number 616003

๐Ÿ‡ต๐Ÿ‡ฑ

Rybnik, Poland

Investigational Site Number 616001

๐Ÿ‡ต๐Ÿ‡ฑ

Warszawa, Poland

Investigational Site Number 203002

๐Ÿ‡จ๐Ÿ‡ฟ

Olomouc, Czech Republic

Investigational Site Number 840001

๐Ÿ‡บ๐Ÿ‡ธ

New Haven, Connecticut, United States

Investigational Site Number 056003

๐Ÿ‡ง๐Ÿ‡ช

Namur, Belgium

Investigational Site Number 056001

๐Ÿ‡ง๐Ÿ‡ช

Leuven, Belgium

Investigational Site Number 203003

๐Ÿ‡จ๐Ÿ‡ฟ

Novy Jicin, Czech Republic

Investigational Site Number 643004

๐Ÿ‡ท๐Ÿ‡บ

Saint-Petersburg, Russian Federation

Investigational Site Number 643001

๐Ÿ‡ท๐Ÿ‡บ

Moscow, Russian Federation

Investigational Site Number 804004

๐Ÿ‡บ๐Ÿ‡ฆ

Kharkov, Ukraine

Investigational Site Number 643002

๐Ÿ‡ท๐Ÿ‡บ

Moscow, Russian Federation

Investigational Site Number 056005

๐Ÿ‡ง๐Ÿ‡ช

Kortrijk, Belgium

Investigational Site Number 840007

๐Ÿ‡บ๐Ÿ‡ธ

Burbank, California, United States

Investigational Site Number 840202

๐Ÿ‡บ๐Ÿ‡ธ

Fort Meyers, Florida, United States

Investigational Site Number 840009

๐Ÿ‡บ๐Ÿ‡ธ

Atlanta, Georgia, United States

Investigational Site Number 203001

๐Ÿ‡จ๐Ÿ‡ฟ

Praha 2, Czech Republic

Investigational Site Number 250004

๐Ÿ‡ซ๐Ÿ‡ท

Caen Cedex 05, France

Investigational Site Number 250006

๐Ÿ‡ซ๐Ÿ‡ท

Bordeaux, France

Investigational Site Number 250001

๐Ÿ‡ซ๐Ÿ‡ท

Lyon, France

Investigational Site Number 276001

๐Ÿ‡ฉ๐Ÿ‡ช

Mรผnchen, Germany

Investigational Site Number 250002

๐Ÿ‡ซ๐Ÿ‡ท

Paris Cedex 4, France

Investigational Site Number 380004

๐Ÿ‡ฎ๐Ÿ‡น

Genova, Italy

Investigational Site Number 250003

๐Ÿ‡ซ๐Ÿ‡ท

Villejuif, France

Investigational Site Number 380003

๐Ÿ‡ฎ๐Ÿ‡น

Milano, Italy

Investigational Site Number 616002

๐Ÿ‡ต๐Ÿ‡ฑ

Krakow, Poland

Investigational Site Number 616004

๐Ÿ‡ต๐Ÿ‡ฑ

Poznan, Poland

Investigational Site Number 804005

๐Ÿ‡บ๐Ÿ‡ฆ

Donetsk, Ukraine

Investigational Site Number 724001

๐Ÿ‡ช๐Ÿ‡ธ

Madrid, Spain

Investigational Site Number 724002

๐Ÿ‡ช๐Ÿ‡ธ

Barcelona, Spain

Investigational Site Number 804003

๐Ÿ‡บ๐Ÿ‡ฆ

Dnipropetrovsk, Ukraine

Investigational Site Number 804002

๐Ÿ‡บ๐Ÿ‡ฆ

Lviv, Ukraine

ยฉ Copyright 2025. All Rights Reserved by MedPath